| Literature DB >> 15307831 |
Kenneth D Chavin1, Ryan N Fiorini, Stephen Shafizadeh, Gang Cheng, Chidan Wan, Zachary Evans, David Rodwell, Carmen Polito, Julia K Haines, G Mark Baillie, Michael G Schmidt.
Abstract
Cerulenin has been shown to reduce body weight and hepatic steatosis in murine models of obesity by inhibiting fatty acid synthase (FAS). We have shown that attenuating intrahepatocyte lipid content diminished the sensitivity of ob/ob mice to ischemia/reperfusion injury and improved survival after liver transplantation. The mechanism of action is by inhibition of fatty acid metabolism by downregulating PPARalpha, as well as mitochondrial uncoupling protein 2 (UCP2), with a concomitant increase in ATP. A short treatment course of cerulenin prior to I/R injury is ideal for protection of steatotic livers. Cerulenin opens the potential for expanding the use of steatotic livers in transplantation. Copyright 2004 Blackwell MunksgaardEntities:
Mesh:
Substances:
Year: 2004 PMID: 15307831 DOI: 10.1111/j.1600-6143.2004.00546.x
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086